EGFR and head and neck squamous cell carcinoma: The monoclonal anti-EGFR antibody, cetuximab, given with erlotinib for secondary prevention in patients with stage I/II HNSCC (NCT00400374) showed 71% pathologic complete response at the time of surgery, but long-term recurrence has not been reported and this combination does have considerable toxicities [43].